December 24, 2025
Q3 2025 reinforced a clear trend in global pharmaceuticals: neurology is no longer a niche category. It is now one of the most commercially important therapeutic areas for large pharmaceutical companies, anchored by durable multiple sclerosis franchises and accelerated by growth in psychiatry and movement disorders.
The quarter’s revenue leaders demonstrate how neurological diseases are supporting long-term portfolio diversification, offsetting loss-of-exclusivity risk in other categories, and generating consistent multi-billion-dollar revenue streams.
Best-Selling Neurology Drugs in Q3 2025
The table below summarizes company-reported Q3 2025 revenues for the top-selling neurology medicines globally. Figures reflect pharmaceutical segment sales only. Roche revenues were reported in CHF and converted to USD using the average Q3 2025 exchange rate.
| Rank | Company | Drug | Primary Indication Area | Q3 2025 Revenue (USD) |
| 1 | Roche | Ocrevus | Multiple sclerosis | 2.24B |
| 2 | Novartis | Kesimpta | Multiple sclerosis | 1.22B |
| 3 | AbbVie | Botox Therapeutic | Chronic migraine, spasticity | 0.99B |
| 4 | AbbVie | Vraylar | Schizophrenia, bipolar I disorder | 0.93B |
| 5 | Johnson and Johnson | Invega Sustenna | Schizophrenia | 0.93B |
| 6 | Neurocrine Biosciences | Ingrezza | Tardive dyskinesia | 0.69B |
| 7 | Teva | Austedo | Tardive dyskinesia, Huntington disease | 0.62B |
| 8 | Johnson and Johnson | Spravato | Treatment-resistant depression | 0.46B |
| 9 | Biogen | Tysabri | Multiple sclerosis | 0.43B |
Multiple Sclerosis Remains the Commercial Anchor
Multiple sclerosis continues to dominate neurology revenues. Roche’s Ocrevus generated 2.24B in Q3 2025, maintaining its position as the highest-grossing neurology drug worldwide. Strong uptake across both relapsing and primary progressive MS has allowed Ocrevus to remain a central pillar of Roche’s neuroscience business, even as early discussions around biosimilar competition begin to emerge.
Novartis’ Kesimpta delivered 1.22B during the quarter, reflecting continued momentum in relapsing MS. Its once-monthly, self-administered dosing profile is reshaping treatment preferences among neurologists and payers who increasingly prioritize convenience alongside efficacy.
Biogen’s Tysabri generated 0.43B nearly two decades after approval, underscoring the durability of established MS brands when supported by long-term clinical familiarity and defined patient populations.
Psychiatry and Mood Disorders Continue to Scale
Psychiatry remains a second major growth engine within neurology. AbbVie’s Vraylar posted 0.93B in Q3 revenue, supported by its expanding role in schizophrenia and bipolar I disorder. Johnson and Johnson’s Invega Sustenna matched that performance at 0.93B, reinforcing the sustained commercial relevance of long-acting injectable antipsychotics.
Spravato contributed 0.46B for Johnson and Johnson, reflecting steady adoption in treatment-resistant depression and continued expansion of interventional psychiatry as a defined subcategory within neuroscience.
Movement Disorders Are Emerging as a High-Growth Segment
Movement disorders represent one of the fastest-growing areas in neurology. Neurocrine Biosciences’ Ingrezza generated 0.69B in Q3, while Teva’s Austedo reached 0.62B. Both assets benefit from rising diagnosis rates of tardive dyskinesia, broader psychiatric screening, and growing real-world evidence supporting long-term disease management.
Together, these products illustrate how specialized neurological conditions can scale into substantial franchises when diagnostic awareness and treatment confidence improve.
Takeaway
Q3 2025 confirms that neurology has entered a new commercial phase. Multiple sclerosis continues to anchor the category, psychiatry is accelerating, and movement disorders are rapidly maturing into meaningful revenue drivers. For large pharmaceutical companies, neurology now represents one of the most durable and strategically important pillars for long-term growth.
